Study Angiotensin-Converting Enzyme Inhibitors

Angiotensin peptides - the angiotensin converting enzyme inhibitor (ACE), captopril, has anxiolytic activity in both experimental and clinical studies. It has recently been shown that the angiotensin 1 receptor antagonist, losartin, has anxiolytic properties whereas the angiotensin 2 antagonists are inactive. 

Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty Results of the MERCATOR study a multicenter, randomized, double-blind placebo-controlled trial, Circulation 1992 86(1) 100-1 10. 

Clinical effects Angiotensin-converting enzyme inhibitors improve symptoms, New York Heart Association (NYHA) functional class, and exercise capacity in patients with HF The Captopril Multicenter Research Group (6) showed that captopril treatment improved the NYHA class in 61% of patients compared with only 24% of patients taking placebo over a 12-week period, Treadmill exercise time improved throughout the 12 weeks of the study in 24% of captopril-treated patients, but in none of the placebo-treated patients. 

Konstam MA, Kronenberg MW, Rousseau Mp et al, Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction, SOLVD (Studies of Left Ventricular Dysfunction) Investigators, Circulation 1993 88 2277-2283. 

Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study, N Engl J Med 1993 329 1-7. 

Angiotensin-converting enzyme inhibitors have been tested for possible prevention of the restenosis that frequently occurs after coronary dilation. These studies were undertaken based on an experimental... 

Yusuf, S., Sleight, P., Pogue, J., et al. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl JMed 342 145-153. 

The same authors also applied capillary electrophoresis to the study of benazepril hydrochloride and several angiotensin-converting enzyme inhibitors [43]. Separation of the compounds was performed by means of two phosphate buffers (each 0.1 M) at pH 7 and 6.25, respectively [42], Due to the highest selectivity of the first mentioned running buffer, the same system has been applied for the quantification of benazepril and other compounds in their corresponding pharmaceutical formulations. It was found that the possibility of simultaneous identification and quantification of the active ingredient in the finished products was especially attractive, and that excipients do not adversely affect the results. This article deals with the validation of some parameters of the quantitative analysis, namely linearity, precision, accuracy, and robustness [43],... 

Packer M, Poole-Whson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999 100(23) 2312-18. 

Echemann M, Zannad F, Briancon S, JuUhere Y, Mertes PM, Virion JM, Villemot JP. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction the EPICAL study. Am Heart J 2000 139(4) 624-31. 

Fogari R, Zoppi A, Tettamanti F, Malamani GD, Tinelli C, Salvetti A. Effects of nifedipine and indometha-cin on cough induced by angiotensin-converting enzyme inhibitors a double-blind, randomized, cross-over study. J Cardiovasc Pharmacol 1992 19(5) 670-3. 

Saruta T, Arakawa K, limura O, Abe K, Matsuoka H, Nakano T, Nakagawa M, Ogihara T, Kajiyama G, Hiwada K, Fujishima M, Nakajima M. Difference in the incidence of congh induced by angiotensin converting enzyme inhibitors a comparative study using imidapril hydrochloride and enalapril maleate. Hypertens Res 1999 22(3) 197-202. 

McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. Sibutramine in Hypertensives Clinical Study Group. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002 16(1) 5-11. 

JafarT, Schmid C, Landa M, Giatras l,Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S,de Jong PE, de Zeeuw D, Lau J, Levey A, for the ACE-inhibition in progressive renal disease Study Group. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease a meta-analysis of patient-level data. Ann Intern Med 2001 135 73-87. 

---